• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Advertisement

Organisation › Details

Sanofi (Group) [since May 2011]

Sanofi-aventis is the world's third largest pharmaceutical company, ranking number one in Europe. Backed by a world-class R&D organization, Sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases, central nervous system, internal medicine, and vaccines. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). *

 

	Start	2011-05-06 renamed
	Predecessor	Sanofi-Aventis (Group)
	Industry	pharmaceutical
	Person	Brandicourt, Olivier (Sanofi 201508–201908 CEO before CEO of Bayer HealthCare before Pfizer Inc RETIRED 9/19)
	Person 2	Contamine, Jérôme (Sanofi 2009–201809 CFO RETIRED 9/18)
	Region	Paris
	Country	France
	Street	174 avenue de France
	City	75635 Paris
	Tel	+33-1-5377-4000
		Address record changed: 2012-01-11
Basic data	Employees	I: 50,001 to 100,0 (2019-02-06)
	Currency	EUR
	Annual sales	34,463,000,000 (sales, net, consolidated (2018) 2018-12-31)
	Profit	4,410,000,000 (2018-12-31)
	Cash	2,633,000,000 (2018-12-31)
		* Document for �About Section�:
		Record changed: 2019-12-03

Advertisement

More documents for Sanofi (Group) [since May 2011]

• [1] Sanofi S.A.. (2/24/20). "Press Release: Sanofi to Create New Industry Leading European Company to Provide Active Pharmaceutical Ingredients (API)". Paris....
• [2] Nurix Therapeutics, Inc.. (1/9/20). "Press Release: Nurix Therapeutics and Sanofi Establish Strategic Collaboration to Develop Novel Targeted Protein Degradation Therapies". San Francisco, CA....
• [3] Evotec SE. (12/18/19). "Press Release: Evotec Expands Service Agreement with Sanofi to Create a Centralised Global Sample Management Hub in Toulouse". Hamburg....
• [4] Sanofi S.A.. (12/9/19). "Press Release: Sanofi to Acquire Synthorx to Bolster Its Immuno-oncology Pipeline for $2.5 Billion". Paris & San Diego, CA....
• [5] Ligand Pharmaceuticals Inc.. (12/2/19). "Press Release: Ligand Enters into Worldwide OmniAb Platform License Agreement with Sanofi". San Diego, CA....
• [6] Eligo Bioscience. (9/17/19). "Press Release: Eligo Bioscience Strengthens Its Leadership and Development Team". Paris....
• [7] Novartis AG. (8/30/19). "Press Release: Novartis Ofatumumab Demonstrates Superiority versus Aubagio in Two Head-to-head Phase III Multiple Sclerosis Studies". Basel....
• [8] Sanofi S.A.. (8/28/19). "Press Release: U.S. District Court Invalidates Amgen Patent Claims Targeting PCSK9". Paris & Tarrytown, NY....
• [9] Exscientia Ltd.. (8/5/19). "Press Release: Sanofi Exercises Option on Exscientia-designed Bispecific Small Molecule for Treatment of Immunological Conditions"....
• [10] MyoKardia, Inc.. (7/18/19). "Press Release: MyoKardia Announces HCM Program Updates". South San Francisco, CA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2020. Made in Germany.